Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of SGN-CD33A in AML Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myeloid leukemia, positive for CD33~* Eastern Cooperative Oncology Group status of 0 or 1~* Adequate baseline renal and hepatic function~* Central venous access~* Either achieved complete remission (greater than 12 weeks in duration) with initial induction/consolidation and have experienced relapse of disease or declined treatment with high-dose induction/consolidation~* Bone marrow blasts greater than or equal to 5% for relapsed patients, or greater than or equal to 20% for untreated patients~Exclusion Criteria:~* Inadequate lung function~* Prior allogeneic stem cell transplant, except for a specific cohort~* High-dose chemotherapy within 4 weeks of study drug~* Antileukemia treatment within 14 days of study drug (other than hydroxyurea or 6-mercaptopurine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGN-CD33A + HMA (Type: EXPERIMENTAL): SGN-CD33A with hypomethylating agent
- SGN-CD33A Monotherapy (Type: EXPERIMENTAL): SGN-CD33A

Based on this trial design, predict the completion outcome and termination type (if applicable).